Subcutaneous ω-Conotoxins Alleviate Mechanical Pain in Rodent Models of Acute Peripheral Neuropathy

Md Mahadhi Hasan1, Hana Starobova1, Alexander Mueller1

  • 1Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia.

Marine Drugs
|March 6, 2021
PubMed

Insights

ω-conotoxins MVIIA and GVIA effectively treat mechanical pain in rodent models of postsurgical pain and oxaliplatin-induced neuropathy. These N-type calcium channel blockers showed no adverse locomotor effects, though they were ineffective in cisplatin-induced neuropathy.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pain Research

Background:

  • Peripheral N-type voltage-gated calcium channels (CaV2.2) are implicated in pain signaling.
  • The specific efficacy of ω-conotoxins targeting these channels in various pain models remains underexplored.

Purpose of the Study:

  • To investigate the peripheral analgesic effects of ω-conotoxins MVIIA, GVIA, and CVIF.
  • To evaluate their efficacy in rodent models of postsurgical pain (PSP), cisplatin-induced neuropathy (CisIPN), and oxaliplatin-induced neuropathy (OIPN).

Main Methods:

  • Intraplantar administration of ω-conotoxins MVIIA, GVIA, and CVIF in rodent pain models.
  • Assessment of mechanical and thermal paw withdrawal thresholds (PWT).
  • Evaluation of locomotor activity to determine side effects.

Main Results:

  • ω-conotoxin MVIIA significantly alleviated mechanical allodynia in the PSP model.
  • MVIIA and GVIA demonstrated significant efficacy in reducing mechanical pain in the OIPN model, with low ED50 values.
  • No ω-conotoxins were effective in the CisIPN model.
  • No significant locomotor side effects were observed with intraplantar administration.

Conclusions:

  • Intraplantar ω-conotoxin MVIIA effectively treats incision-induced mechanical allodynia.
  • ω-conotoxins GVIA and MVIIA are effective in managing OIPN-associated mechanical pain without causing locomotor impairment.
  • ω-conotoxin CVIF showed no efficacy, suggesting it targets a different subset of CaV2.2 channels than those involved in skin nociception.

Related Concept Videos